全文获取类型
收费全文 | 28618篇 |
免费 | 2520篇 |
国内免费 | 1707篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 427篇 |
妇产科学 | 110篇 |
基础医学 | 3770篇 |
口腔科学 | 95篇 |
临床医学 | 2539篇 |
内科学 | 12515篇 |
皮肤病学 | 187篇 |
神经病学 | 137篇 |
特种医学 | 513篇 |
外国民族医学 | 4篇 |
外科学 | 1003篇 |
综合类 | 5546篇 |
现状与发展 | 12篇 |
预防医学 | 1972篇 |
眼科学 | 32篇 |
药学 | 2149篇 |
9篇 | |
中国医学 | 1288篇 |
肿瘤学 | 528篇 |
出版年
2024年 | 25篇 |
2023年 | 342篇 |
2022年 | 424篇 |
2021年 | 778篇 |
2020年 | 825篇 |
2019年 | 961篇 |
2018年 | 855篇 |
2017年 | 945篇 |
2016年 | 1140篇 |
2015年 | 1152篇 |
2014年 | 1795篇 |
2013年 | 1910篇 |
2012年 | 1701篇 |
2011年 | 2033篇 |
2010年 | 1513篇 |
2009年 | 1356篇 |
2008年 | 1419篇 |
2007年 | 1545篇 |
2006年 | 1518篇 |
2005年 | 1225篇 |
2004年 | 1081篇 |
2003年 | 954篇 |
2002年 | 873篇 |
2001年 | 880篇 |
2000年 | 725篇 |
1999年 | 580篇 |
1998年 | 516篇 |
1997年 | 482篇 |
1996年 | 445篇 |
1995年 | 442篇 |
1994年 | 376篇 |
1993年 | 327篇 |
1992年 | 289篇 |
1991年 | 212篇 |
1990年 | 166篇 |
1989年 | 137篇 |
1988年 | 143篇 |
1987年 | 117篇 |
1986年 | 94篇 |
1985年 | 109篇 |
1984年 | 87篇 |
1983年 | 58篇 |
1982年 | 61篇 |
1981年 | 53篇 |
1980年 | 47篇 |
1979年 | 31篇 |
1978年 | 40篇 |
1977年 | 27篇 |
1976年 | 8篇 |
1973年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
目的:分析延续护理干预对慢性乙型肝炎患者抗病毒治疗依从性的影响。方法:研究选取2017年1月~2017年12月某院肝二病区收治的112例乙型肝炎患者和2018年1月~2018年12月收治的98例乙型肝炎病毒患者作为研究对象,所有患者均进行抗病毒治疗,回顾性分析患者的病历资料。将2017年收治的112例患者作为常规组实施常规护理,将2018年收治的98例患者的作为研究组实施延续性护理,比较两组的护理效果。结果:研究组的治疗依从率为93.88%(92例),远高于常规组的77.68%(87例),两组数据比较存在统计学意义(P<0.05)。结论:延续性护理措施可以有效提高慢性乙型肝炎抗病毒治疗的依从性,可以在临床中推广使用。 相似文献
13.
Auda A. Eltahla Fabio Luciani Peter A. White Andrew R. Lloyd Rowena A. Bull 《Viruses》2015,7(10):5206-5224
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens. 相似文献
14.
15.
16.
17.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C 下载免费PDF全文
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
18.
S. Nishida J. J. Gaynor N. Nakamura F. Butt H. G. Illanes J. Kadono G. W. Neff D. M. Levi J. I. Moon G. Selvaggi T. Kato P. Ruiz A. G. Tzakis J. R. Madariaga 《American journal of transplantation》2006,6(1):140-149
A retrospective study of 1058 liver transplant recipients was performed to determine: (i) the incidence, etiology, timing, clinical features and treatment of refractory ascites (RA), (ii) risk factors for RA development, (iii) predictors of RA disappearance, (iv) predictors of survival following RA and (v) the impact of RA on patient survival. Sixty-two patients (5.9%) developed RA and its disappearance occurred in 27/62 cases. Patients having hepatitis C virus (HCV) had a significantly higher hazard rate of developing RA (p < 0.00001). No other baseline characteristic was associated with RA. Cox stepwise regression analysis of the hazard rate of RA disappearance found two significant factors: HCV recurrence as the reason for developing RA implied a poorer outcome (p = 0.006), whereas an unknown reason implied a favorable outcome (p = 0.02). In addition, survival following RA was significantly poorer among patients having bacterial peritonitis or HCV recurrence. Finally, the mortality rate was significantly (nearly 8.6 times) higher in patients following RA development while it was ongoing (p < 0.00001); however, if the RA disappeared, then the additional risk of death also disappeared. This study illustrates the importance of developing an optimal treatment strategy to (i) effectively treat RA if it develops and (ii) prevent hepatitis C recurrence. 相似文献
19.
Marieke C Wichers Gunter Kenis Carsten Leue Ger Koek Geert Robaeys Michael Maes 《Neuropsychopharmacology》2006,60(1):77-79
BACKGROUND: Major depression has been associated cross-sectionally with increased cell-mediated immune activation but causality has been difficult to establish. This study prospectively investigated the hypothesis that baseline level of immune activation predicts the development of depression during interferon-alpha (IFN-alpha) treatment. METHODS: Sixteen hepatitis C patients without psychiatric disorder underwent IFN-alpha treatment. Proinflammatory and anti-inflammatory cytokines were determined before starting treatment. Presence of a major depressive disorder (MDD) was assessed at baseline and several times during treatment. RESULTS: Baseline soluble interleukin-2 receptor (sIL-2r), interleukin-6 (IL-6), and interleukin-10 (IL-10) concentrations were significantly increased in the five subjects that developed MDD during treatment compared with those that did not, with standardized effect sizes of 1.08, 1.16, and 1.25, respectively, controlling for marijuana use, cigarette smoking, and baseline level of depressive symptoms. CONCLUSIONS: Results suggest that increased immune activation, rather than an epiphenomenon, is a causal risk factor for the development of MDD. 相似文献
20.
Dino Donataccio Francine Roggen Chantal De Reyck Catherine Verbaandert Monique Bodeus Jan Lerut 《Transplant international》2006,19(1):38-43
The use of livers from anti-hepatitis B core (HBc) positive donors can alleviate donor shortage. Nineteen of 367 (6%) adults receiving anti-HBc positive allografts [three were hepatitis B antigen (HBsAg) negative, hepatitis B antibody (HBsAb) positive; four were HBsAg positive and 12 were not exposed to hepatitis B viral (HBV) infection] were retrospectively reviewed. In HBsAg negative recipients, immunoprophylaxis (IP) was guided by viral serology and immunohistochemistry (IH) of day 0 and day 7 liver biopsies. If IH was negative, IP was stopped. None of three HBsAg negative, HBsAb positive recipients infected; one (replicating) of four HBsAg positive recipients reinfected and seven of eight (87.5%) HBsAg, HBsAb negative recipients, who did not receive long-term IP, infected after a median time of 2 years (range 1-5); one patient died of liver failure. Four HBsAg, HBsAb negative recipients, receiving life-long IP, remained infection free. Anti-HBc positive donor livers must be directed selectively first to HBsAg positive recipients, next to recipients having HBV antibodies and finally to HBV-naive recipients. Identification of both donor and recipient risk factors for HBV infection before transplantation allows indiscriminate use of antiviral prophylaxis. The necessity for IP therapy should be guided by HBV-DNA testing of donor liver tissue and serum. IH of early liver biopsies is an unreliable marker for predicting antiviral treatment requirements. 相似文献